Ridgeback Capital
Crossover fundMiami · Seed–Late Stage · 1 people tracked
Also known as MANDALAY FINANCIAL, L.L.C.
Find your way into Ridgeback Capital
1 people in our graph share verified history with the Ridgeback Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Ridgeback Capital invests in private and public healthcare companies dedicated to developing transformative, life-saving and life-changing therapies. The firm emphasizes patient capital, reflecting founder Dr. Wayne Holman's belief that meaningful healthcare advances often take many years to materialize and require long-term backing for new technologies and companies to succeed. Over more than two decades, the firm's principal has funded over 100 public and private biopharma companies supporting research and development addressing unmet medical needs.
Source: firm website, verified Aug 3, 2026.
Team · 1 people
from the firm's websiteWhat they invest in
from 11 of 19 portfolio companiesBiotech ×11Healthtech ×11Medical Devices ×5Deep Tech ×2Digital Health ×2AgTech ×1AI & Machine Learning ×1
HQs:United States×8France×1
Investments · 19 tracked
founders shown can be your intro pathBy year:2024 · 12016 · 12014 · 13 dated
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
BiotechHealthtechMedical DevicesAbingdon, Oxfordshire, US
Adrian Rawcliffe(Chief Executive Officer and Director)inGavin Wood(Chief Financial Officer)inWilliam Bertrand(Chief Operating Officer)inJohn Lunger(Chief Patient Supply Officer)inElliot Norry(Chief Medical Officer)inJoanna Brewer(Chief Scientific Officer)
Co-investorsAvoro Capital AdvisorsEight Roads VenturesF-Prime CapitalForesite CapitalNew Enterprise Associates (NEA)
MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients.
BiotechHealthtechMedical Devices
Scott Koenig(Director)inEric Risser(President and Chief Executive Officer)in
Co-investorsHavencrest Capital ManagementRiverVest Venture PartnersSanofi VenturesLa CaisseTPG
Patrick Mahaffy(Founder)in
Co-investorsAisling CapitalNew Enterprise Associates (NEA)
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalLumira Ventures+5 more
Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions.
BiotechHealthtechSan Francisco, US
Thomas B. Neff(Executive Officer, Director)Frank H. Valone(Executive Officer)inK. Peony Yu(Executive Officer)inPat Cotroneo(Executive Officer)in
BoardRory B. Riggs(Director)Kalevi Kurkijarvi(Director)
Co-investorsAvalon BioVenturesScientia VenturesMaverick Ventures
GENFIT is a biopharmaceutical company developing therapies for rare, life-threatening liver diseases, with an R&D pipeline of eight programs focused on acute-on-chronic liver failure, hepatic encephalopathy, cholangiocarcinoma, and urea cycle disorders/organic acidemias.
BiotechHealthtech
Co-investorsredalpine
Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects.
BiotechHealthtechBurlingame, US
Daniel J. Capon(Director)Carin Mueller Rollins(Co-Founder & Chief Operating Officer)Harold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)inHarold E. "Barry" Selick(Chief Executive Officer & Director)Paul Brunetta(Chief Medical Officer)in
Co-investorsPoint72Agent CapitalBaruch Future VenturesInVivium Capital
Intercept Pharmaceuticals develops and commercializes treatments for rare and serious liver and other diseases, with a focus on conditions such as primary biliary cholangitis.
BiotechHealthtechMedical Devices
Co-investorsAisling CapitalBioBritSamsara BioCapital
Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases.
BiotechDigital HealthHealthtechCambridge, US
PETER M. HECHT(Executive Officer, Director)inMARK G. CURRIE(Executive Officer)inHALLEY E. GIBLERT(Executive Officer)THOMAS GRANEY(Executive Officer)THOMAS A. MCCOURT(Executive Officer)in
BoardTERRANCE G. MCGUIRE(Director)
Co-investorsF-Prime CapitalMountain Group CapitalVenrockMaverick VenturesPolaris Partners
Regeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease.
BiotechHealthtechTarrytown, US
Co-investorsSanderling VenturesvenBio PartnersWireframe Ventures
Sangamo Therapeutics develops gene-editing therapeutics using zinc finger and modular integrase platforms to treat genetic diseases including hemophilia, Fabry disease, and neuropathy.
BiotechDeep TechHealthtechMedical DevicesUnknown based on the provided page content, US
Sandy Macrae(Chief Executive Officer)in
Co-investorsCalifornia Technology VenturesFoothill VenturesForesite Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ALDRBMRNCelgeneThumbnail for Exonics TherapeuticsTSROUTHR
Exits · 3
2 IPOs · 1 acquisitionsAdaptimmuneOTC: ADAPYMacrogenics IncNASDAQ: MGNXIntercept Pharmaceuticalsacq. by Alfasigma
Portfolio news
latest coverage across their companiesSangamo Therapeutics · tipranks.com · Aug 13, 2026
Ironwood Pharmaceuticals · marketbeat.com · Aug 11, 2026
Cellectis · investing.com · Aug 6, 2026
Adaptimmune · trial.medpath.com · Oct 27, 2025
Frequently asked questions
- How many investments has Ridgeback Capital made?
- Ridgeback Capital has 19 tracked investments, 3 of which have exited, including 1 dated in the last 24 months.
- What stage does Ridgeback Capital invest at?
- Ridgeback Capital invests at the Seed, Late Stage stages.
- What sectors does Ridgeback Capital focus on?
- Ridgeback Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Ridgeback Capital located?
- Ridgeback Capital is headquartered in Miami, US.
- Who does Ridgeback Capital co-invest with?
- Ridgeback Capital most often shares deals with Aisling Capital, Kleiner Perkins, New Enterprise Associates (NEA), among 32 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
Sanderling Ventures is one of the oldest investment firms focused on building new biomedical companies, working in close partnership with entrepreneurs.
T. Rowe Price is a global asset management firm that actively invests across markets to pursue opportunities on behalf of its clients.